The case was consulted with cardiologists and considering his high d-dimer, they advised chest CT angiography with a high suspicion for pulmonary embolism, however, in view of his unstable condition CT angiography could not have been carried out
L bt sau khi pha vi nc ct ch tim trong vng 2 gi vi nhit phng v 8 gi nu bo qun 0 n 5 C
Results include 7.5% reduction in body weight from baseline at day 36 Weight loss continued to at least 4 weeks after last dose administered MET-097, incorporating Metseras HALO platform technology, achieved 380-hour half-life Potential for monthly dosing and dosing regimens without titration Metsera launching Phase 2b trials in Q4 2024, with data anticipated in first half of 2025 NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable, fully-biased GLP-1 receptor agonist
Altered mitochondrial mass and low mitochondrial membrane potential of immune cells in patients with HBV infection and correlation with liver inflammation
Diabetes Care 2025;48(Supplement 1):S283-305.PubMed 928
D-carnitine Carnitine exists in two stereoisomeric forms, L-carnitine and D-carnitine, due to the presence of an asymmetric carbon atom (the second carbon in the chain)
